HLS Therapeutics (TSX:HLS) GF Value Rank: 9 (As of Jul. 12, 2026) — 125% Above Median


TSX:HLS HLS Therapeutics Inc TSX:HLS
66 GF Score
Price C$4.31
GF Value C$4.51
Valuation Fairly Valued
! 4 Warning Signs
View Full Analysis

What is HLS Therapeutics GF Value Rank?

HLS Therapeutics TSX:HLS +0.70% 66 GF Value Rank is 9 as of Jul. 12, 2026, which is 125% above its 10-year median of 4.00. GuruFocus rates TSX:HLS with a GF Score™ of 66/100 and a GF Value™ of C$4.51 (Fairly Valued). The stock has 4 warning signs investors should review.

HLS Therapeutics has the GF Value Rank of 9.

GF Value Rank evaluates the exclusive GuruFocus valuation and performance of a stock, rated on a scale from 1 to 10. It is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.

GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).

We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.

After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.

A higher score indicates a stock with a relatively low valuation and substantial potential for outperformance. Conversely, a lower score often reflects stocks that are either highly overvalued or deeply undervalued, both of which tend to underperform.

Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.


HLS Therapeutics GF Value Rank Related Terms


TSX:HLS vs ZTS, UTHR: GF Value Rank Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, HLS Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


HLS Therapeutics GF Value Rank vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, HLS Therapeutics's GF Value Rank distribution charts can be found below:

* The bar in red indicates where HLS Therapeutics's GF Value Rank falls into.


TSX:HLS
66GF Score
HLS Therapeutics Inc TSX:HLS
GF Value Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about GF Value Rank →
What does a GF Value Rank of 9 mean?
HLS Therapeutics (TSX:HLS) has a GF Value Rank of 9 as of Jul. 12, 2026. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on HLS Therapeutics and its competitors. This is 125% above median its historical median of 4.00. Over the past decade, HLS Therapeutics' GF Value Rank has ranged from 1.00 to 10.00.
Is HLS Therapeutics' GF Value Rank too high?
HLS Therapeutics' current GF Value Rank of 9 is 125% above median its 10-year median of 4.00. Over the past 10 years, this metric has ranged from a low of 1.00 to a high of 10.00. Overall, HLS Therapeutics has a GF Score™ of 66/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does HLS Therapeutics' GF Value Rank compare to ZTS and UTHR?
HLS Therapeutics' GF Value Rank of 9 can be compared against companies in the Drug Manufacturers industry. Historically, HLS Therapeutics' own GF Value Rank has ranged from 1.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good GF Value Rank for a Drug Manufacturers company?
A good GF Value Rank depends on the Drug Manufacturers industry context. However, GF Value Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high GF Value Rank mean?
A high GF Value Rank can signal that a stock is expensive relative to its fundamentals. GF Value Rank is given based on historical multiples along with past returns, growth and future estimates of the business' performance. View historical data on HLS Therapeutics and its competitors. HLS Therapeutics's current GF Value Rank is 9, which is 125% above median its own 10-year median of 4.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is HLS Therapeutics stock overvalued right now?
Based on GuruFocus' analysis, HLS Therapeutics (TSX:HLS) is currently considered Fairly Valued. The stock's GF Value™ is C$4.51, compared to a current price of C$4.31 — trading 4.4% below its estimated fair value. The current GF Value Rank is 9, which is 125% above median its 10-year median of 4.00. HLS Therapeutics' overall GF Score™ is 66/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is GF Value Rank calculated?
GF Value Rank is calculated from a company's financial statements. For HLS Therapeutics (TSX:HLS), the current GF Value Rank is 9 as of Jul. 12, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is HLS Therapeutics (TSX:HLS) Overvalued in 2026?

Based on GuruFocus' analysis, HLS Therapeutics stock appears to be undervalued. The current stock price of C$4.31 is trading 4.4% below its estimated GF Value™ of C$4.51. GuruFocus considers HLS Therapeutics to be Fairly Valued.

Key valuation signals for TSX:HLS:

  • GF Value Rank: 9 (125% above median its 10-year median of 4.00)
  • GF Value™: C$4.51 vs. price of C$4.31 (4.4% below fair value)
  • GF Score™: 66/100 with 4 warning signs

No single metric tells the full story. See the TSX:HLS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


HLS Therapeutics Business Description

Other Exchanges HLTRF:USA74D:Germany
Address 10 Carlson Court, Suite 701, Etobicoke, Toronto, ON, CAN, M9W 6L2
HLS Therapeutics Inc is a specialty pharmaceutical company. It is focused on the acquisition and commercialization of branded pharmaceutical products in the North American markets. The company's products include Clozaril, Vascepa, CSAN Pronto, and others. The company earns revenue in the form of product sales and royalties, out of which product sales contribute to the majority of the revenue. The company operates in Canada, the United States, and the Rest of world, with the majority of its revenue generated from Canada.
66GF Score

Get the complete analysis for TSX:HLS

GF Value Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

C$4.31
Price
C$4.51
GF Value